Your browser doesn't support javascript.
loading
Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies.
Doepker, Laura E; Danon, Sonja; Harkins, Elias; Ralph, Duncan K; Yaffe, Zak; Garrett, Meghan E; Dhar, Amrit; Wagner, Cassia; Stumpf, Megan M; Arenz, Dana; Williams, James A; Jaoko, Walter; Mandaliya, Kishor; Lee, Kelly K; Matsen, Frederick A; Overbaugh, Julie M.
Afiliação
  • Doepker LE; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
  • Danon S; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
  • Harkins E; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
  • Ralph DK; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
  • Yaffe Z; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
  • Garrett ME; Medical Scientist Training Program, University of Washington School of Medicine, Seattle, United States.
  • Dhar A; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
  • Wagner C; Molecular and Cellular Biology Graduate Program, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, United States.
  • Stumpf MM; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
  • Arenz D; Department of Statistics, University of Washington, Seattle, United States.
  • Williams JA; Medical Scientist Training Program, University of Washington School of Medicine, Seattle, United States.
  • Jaoko W; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
  • Mandaliya K; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
  • Lee KK; Department of Medicinal Chemistry, University of Washington, Seattle, United States.
  • Matsen FA; Department of Medicinal Microbiology, University of Nairobi, Nairobi, Kenya.
  • Overbaugh JM; Coast Provincial General Hospital, Women's Health Project, Mombasa, Kenya.
Elife ; 102021 01 11.
Article em En | MEDLINE | ID: mdl-33427196
Nearly four decades after the human immunodeficiency virus (HIV for short) was first identified, the search for a vaccine still continues. An effective immunisation would require elements that coax the human immune system into making HIV-specific antibodies ­ the proteins that can recognise, bind to and deactivate the virus. Crucially, antibodies can also help white blood cells to target and destroy cells infected with HIV. This 'antibody-dependent cellular cytotoxicity' could be a key element of a successful vaccine, yet it has received less attention than the ability for antibodies to directly neutralize the virus. In particular, it is still unclear how antibodies develop the ability to flag HIV-infected cells for killing. Indeed, over the course of an HIV infection, an immune cell goes through genetic changes that tweak the 3D structure of the antibodies it manufactures. This process can improve the antibodies' ability to fight off the virus, but it was still unclear how it would shape antibody-dependent cellular cytotoxicity. To investigate this question, Doepker et al. retraced how the genes coding for six antibody families changed over time in an HIV-carrying individual. This revealed that antibodies could not initially trigger antibody-dependent cellular cytotoxicity. The property emerged and improved thanks to two types of alterations in the genetic sequences. One set of changes increased how tightly the antibodies could bind to the virus, targeting sections of the antibodies that can often vary. The second set likely altered the 3D structure in others ways, potentially affecting how antibodies bind the virus or how they interact with components of the immune system that help to kill HIV-infected cells. These alterations took place in segments of the antibodies that undergo less change over time. Ultimately, the findings by Doepker et al. suggest that an efficient HIV vaccine may rely on helping antibodies to evolve so they can bind more tightly to the virus and trigger cellular cytotoxicity more strongly.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / HIV-1 / Citotoxicidade Celular Dependente de Anticorpos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / HIV-1 / Citotoxicidade Celular Dependente de Anticorpos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article